X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
X4 Pharmaceuticals, Inc. (XFOR)
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the event, click here. The event will focus on new interim results from an ongoing Phase 2 clinical trial exploring the use of mavorixafor as a once-daily oral treatment in patients with chronic neutropenia (CN). The data to be presented will include hematological results from at least 15 study participants treated with either mavorixafor monotherapy or mavorixafor in combination with stable doses of injectable granulocyte colony-stimulating factor (G-CSF). Physician expert commentary on the clinical results and the high unmet need in CN will also be included as part of the event. As previously communicated, the company plans to initiate a global, pivotal Phase 3 clinical trial in the current quarter tha
Show less
Read more
Impact Snapshot
Event Time:
XFOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XFOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XFOR alerts
High impacting X4 Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
XFOR
News
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $5.00 price target on the stock.MarketBeat
- X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewswire
XFOR
Earnings
- 5/7/24 - Miss
XFOR
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 8-K
- 6/11/24 - Form 4
- XFOR's page on the SEC website